Esophageal Cancer Treatment–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (12/03/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Esophageal Cancer

Added Shapiro et al. as reference 24.

Revised text to state that with a median follow-up of 84 months, preoperative chemoradiation was found to improve median overall survival (OS) from 24 months in the surgery-alone group to 48.6 months. Added that median OS for patients with squamous cell carcinomas was 81.6 months in the preoperative chemoradiation group compared with 21.1 months in the surgery-alone group; for patients with adenocarcinomas, the median OS was 43.2 months in the preoperative chemoradiation group compared with 27.1 months in the surgery-alone group.

Added text to state that with a median follow-up of 84 months, the 5-year progression-free survival was 44% in the preoperative chemoradiation group compared with 27% in the surgery-alone group.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Esophageal Cancer

Next section >
About This PDQ Summary